GeoVax receives BARDA award up to $45M for Phase 2b COVID-19 vaccine trial

GeoVax Labs, Inc.

Direct award to GeoVax of ~$24.3M, potentially increasing to $45M, for manufacturing and clinical trial support.
BARDA separately commits ~$343M from Project NextGen for a CRO to execute the 10,000-participant Phase 2b study.
Phase 2b double-blinded trial will compare GeoVax's GEO-CM04S1 against an FDA-approved mRNA COVID-19 vaccine.
Study is part of HHS Project NextGen, a $5B initiative for next-generation COVID-19 vaccines and therapeutics.
GeoVax's dual-antigen vaccine candidate aims to induce durable antibody and T-cell immunity against variants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.